Eliem Therapeutics Probability of Future Stock Price Finishing Over 21.69
| ELYMDelisted Stock | USD 3.09 0.06 1.90% |
Eliem |
Eliem Therapeutics Target Price Odds to finish over 21.69
The tendency of Eliem Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 21.69 or more in 90 days |
| 3.09 | 90 days | 21.69 | near 1 |
Based on a normal probability distribution, the odds of Eliem Therapeutics to move over $ 21.69 or more in 90 days from now is near 1 (This Eliem Therapeutics probability density function shows the probability of Eliem Stock to fall within a particular range of prices over 90 days) . Probability of Eliem Therapeutics price to stay between its current price of $ 3.09 and $ 21.69 at the end of the 90-day period is about 86.88 .
Given the investment horizon of 90 days Eliem Therapeutics has a beta of -0.35 suggesting as returns on the benchmark increase, returns on holding Eliem Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Eliem Therapeutics is likely to outperform the market. Additionally Eliem Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Eliem Therapeutics Price Density |
| Price |
Predictive Modules for Eliem Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eliem Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eliem Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eliem Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eliem Therapeutics is not an exception. The market had few large corrections towards the Eliem Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eliem Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eliem Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.07 | |
β | Beta against Dow Jones | -0.35 | |
σ | Overall volatility | 1.74 | |
Ir | Information ratio | -0.24 |
Eliem Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eliem Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eliem Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eliem Therapeutics is now traded under the symbol CLYM. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Eliem Therapeutics is not yet fully synchronised with the market data | |
| Eliem Therapeutics generated a negative expected return over the last 90 days | |
| Eliem Therapeutics has high historical volatility and very poor performance | |
| Eliem Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN |
Eliem Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eliem Stock often depends not only on the future outlook of the current and potential Eliem Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eliem Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 106.8 M |
Eliem Therapeutics Technical Analysis
Eliem Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Eliem Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Eliem Therapeutics. In general, you should focus on analyzing Eliem Stock price patterns and their correlations with different microeconomic environments and drivers.
Eliem Therapeutics Predictive Forecast Models
Eliem Therapeutics' time-series forecasting models is one of many Eliem Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Eliem Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Eliem Therapeutics
Checking the ongoing alerts about Eliem Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eliem Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Eliem Therapeutics is now traded under the symbol CLYM. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Eliem Therapeutics is not yet fully synchronised with the market data | |
| Eliem Therapeutics generated a negative expected return over the last 90 days | |
| Eliem Therapeutics has high historical volatility and very poor performance | |
| Eliem Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |